Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Valion Bio completed formulation work with Shear Kershman Laboratories on a needle-free oral mucosal version of Entolimod using SKL's BioViscid™ delivery platform. Entolimod, the company's lead TLR5 agonist candidate for Acute Radiation Syndrome, is being positioned as a scalable radiation countermeasure amid nuclear-power expansion driven by AI data-center electricity demand.
Key figures
- Drug Name
- Entolimod (BioViscid™ oral mucosal formulation)
- Phase Of Trial
- preclinical formulation development (FDA Animal Rule pathway)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.